COA has held senior roles at a couple of the Giants in Bristol Myers Squibb and J@J.
No doubt in my mind she is in the Big Chair at Acadia with the aspirations of turning it from Medium Pharma to Big Pharma.
Having the keys to all of Neuren’s intellectual property would be by far the best and quickest way to get there.
The question is how this could be achieved given their limited fiscal resources and could they strike a deal that Jon would see as optimising Neuren shareholder value and satisfaction?
To me it’s doubtful but not completely out of the question.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$16.93 |
Change
-0.360(2.08%) |
Mkt cap ! $2.133B | |||
| Open | High | Low | Value | Volume |
| $17.08 | $17.67 | $16.93 | $6.897M | 401.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 2660 | $16.93 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.07 | 1994 | 2 |
View Market Depth
| Last trade - 16.10pm 01/08/2025 (20 minute delay) ? |
| NEU (ASX) Chart |